| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Recent developments showcase Novartis' commitment to innovation in product and service development, particularly with positive drug results such as remibrutinib for multiple sclerosis. However, the company faces significant challenges marked by multiple trial failures, particularly with drugs targeting cardiovascular and cholesterol conditions, which adversely affect their pipeline and investor confidence. The balance of these factors indicates both progress and hurdles in their strategic approach to drug development. Overall, the landscape is characterized by promising advances overshadowed by critical setbacks. |
| The price action of Novartis AG (NVS) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -2.8 is extremely bearish. The market sentiment at -1.1 is very bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. NVS is likely to move down since both trend sentiment and market sentiment are negative. The positive sentiment force for sector is at 0.7, and the negative at -1.8 on 2026-09-08. The forces of Sentiment towards Fundamentals (-4.6), Valuation Sentiment (-2.8), Stock Price Trend (-2.8), and Sector Price Trend (-0.8) will drive down the price. The forces of Market Risk Appetite (1), Price Level Sentiment (1.5), and Option Sentiment (1.5) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| NVS | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | 1%(0.1%) | 137.74 | 4.03% | -30 | 36 | 1 | -13.91% | -1.26% | -2.8 | -2.5 | 7.7% | -1.1 | Wait | 50% | -4.6 | -7.6 |
| 2026-09-07 | 0%(0%) | 0.6 | -2.5 | -0.3 | -2.5 | -1 | ||||||||||
| 2026-09-06 | 0%(0%) | 0.6 | -2.5 | -0.2 | -1.8 | -1 | ||||||||||
| 2026-09-05 | 0%(0%) | 0.6 | -2.5 | -0.1 | -1.1 | -4 | ||||||||||
| 2026-09-04 | 0%(0%) | 160 | 2.34% | 73 | 60 | 34 | -1.88% | 0.06% | 0.6 | 0 | 0.7% | 0.1 | Long | 55% | -1.2 | -1 |
| 2026-09-03 | 0%(0%) | 163.07 | 2.24% | 96 | 66 | 70 | 0.39% | 0.44% | 1.3 | 0.2 | 0.4% | 0.1 | Wait | 50% | -2.2 | -1 |
| 2026-09-02 | 0%(0%) | 162.44 | 2.05% | 99 | 64 | 62 | 0.74% | 0.13% | 0.7 | 0.5 | 2.4% | -0.7 | Wait | 50% | -3.9 | -1 |
| 2026-09-01 | 0%(0%) | 161.25 | 1.85% | 98 | 62 | 80 | 6.04% | 0.45% | 0.9 | 0.9 | 2.7% | -0.4 | Wait | 50% | -3.2 | 5 |
| 2026-08-31 | 0%(0%) | 152.06 | 1.79% | 22 | 46 | 39 | -1.14% | 0% | -0.5 | -0.2 | 0.7% | -0.7 | Short | 55% | -3.4 | -1 |
| 2026-08-30 | 0%(0%) | -0.2 | -0.2 | -1.2 | -3.4 | -1 | ||||||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Novartis AG (NVS) Equity Research Report Wed. Mar 11, 2026 | ||
| 2026-09-08 17:07:22 With multiple drug trial failures, analysts are revising down the stock price targets for Novartis, reflecting lowered valuations based on new information. |
| 2026-09-08 17:07:22 Concerns regarding potential regulatory challenges and market dynamics are influencing perceptions of Novartis and its competitors in the pharma industry. |
| 2026-09-08 17:07:22 The ripple effect of Novartis' trial failures has caused shares of competitors in the biopharmaceutical sector to decline, reflecting broader concerns about similar therapies. |
| 2026-09-08 17:07:22 Articles discuss investor worries regarding the long-term outlook for Novartis due to setbacks in critical drug trials, impacting future earnings prospects. |
| 2026-09-08 17:07:22 Multiple articles highlight how Novartis' recent clinical trial failures have led to significant declines in its stock price, indicating a strong negative sentiment among investors. |
| 2026-09-08 13:46:49 The results of Novartis's trial led to a significant selloff in biopharma stocks, indicating investor concern. |
| 2026-09-08 13:46:49 The failure of Novartis’s drug trial has caused a negative impact on the broader biopharma sector, reflecting industry volatility. |
| 2026-09-08 11:47:38 The repeated setbacks raise major concerns regarding Novartis's future growth and overall market position, especially in light of their recent acquisitions. |
| 2026-09-08 11:47:38 The failures in drug trials have led to a noticeable decline in Novartis's stock value, affecting investor sentiment and causing a broader selloff in the biopharma sector. |
| 2026-09-08 11:47:38 Multiple articles highlight the recurrent failures of Novartis's clinical trials, indicating significant challenges in their drug development efforts. |
| 2026-09-08 09:32:30 The ripple effect of Novartis' trial failures on related companies like Ionis and Royalty Pharma, showcasing interconnected market dynamics. |
| 2026-09-08 09:32:30 Increased scrutiny and pressure on CEO Vas Narasimhan due to recent trial failures and overall performance of the company's pipeline. |
| 2026-09-08 09:32:30 A notable decline in Novartis' stock price following disappointing trial results, indicating investor reactions to product viability. |
| 2026-09-08 09:32:30 Significant setbacks in drug trials for Novartis, particularly with del-desiran, affecting stock performance and investor confidence. |